Business Context and Reporting Period
Company: ORIC Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2025
Reporting Period: Fiscal quarter ended March 31, 2025
Context: The filing serves to announce the company's financial results for the first quarter of 2025 via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. The filing references a press release (Exhibit 99.1) for details on:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide clear values for these metrics; they must be sourced from the attached press release.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that results for the quarter ended March 31, 2025, have been announced.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release by reference but does not include the text of management commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: None identified in the cover sheet.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2025) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Confirm if the company has elected to use the extended transition period for new accounting standards (indicated as "Yes" in the filing).